Jump to the top of the page

Investment Banking

The Quarterly Rx: Q1 2023 U.S. Biopharma Recap

The year kicked off with renewed optimism for the biopharma sector, but “macro” concerns resurfaced to end the quarter. Demand for catalyst-driven offerings remained strong in the public markets, but the private market continued to slow. There is a strong desire to see more SMID-cap M&A to recycle capital into the sector, while reverse mergers continue to provide companies with an alternative path to the public markets. The quarter did see the long-awaited “big M&A” of Seagen by Pfizer, the largest biopharma deal since 2019.

William Blair’s Biopharma team shares perspectives in the Quarterly Rx: Q1 2023 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Cash is Still King, Especially During the Great Iberian Blackout (El Apagón)

    The complete power outage across the Iberian Peninsula last week was a wake-up call. William Blair’s Richard de Chazal outlines five lessons to take away from the event.

    Read more

  • Roper Technologies, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Roper Technologies, Inc. (ROP $557.59), a leading operator and acquirer of high-quality vertical software assets across multiple industries.

    Read more

  • Economics Weekly: From Growth to GARP

    In this Economics Weekly, Richard de Chazal discusses the shift from low, stable inflation to a more volatile regime and its implications for investors, including a potential move from growth investing to GARP (growth at a reasonable price) investing.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures